OKUR Stock Summary and Trading Ideas (Onkure Therapeutics - Class A | NASDAQ:OKUR)

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Ka. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.

Onkure Therapeutics - Class A trades on the NASDAQ stock market under the symbol OKUR.

As of August 10, 2026, OKUR stock price declined to $4.04 with 70,666 million shares trading.

OKUR has a beta of 0.89, meaning it tends to be less sensitive to market movements. OKUR has a correlation of 0.02 to the broad based SPY ETF.

OKUR has a market cap of $163.61 million. This is considered a Micro Cap stock.

Last quarter Onkure Therapeutics - Class A reported $0 in Revenue and -$.31 earnings per share. This fell short of revenue expectation by $-200,000 and exceeded earnings estimates by $.31.

The top ETF exchange traded funds that OKUR belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

OKUR has outperformed the market in the last year with a return of +101.0%, while the SPY ETF gained +23.4%. However, in the most recent history, OKUR shares have underperformed the stock market with its stock returning +2.0% in the last 3 month period and -1.9% for the last 2 week period, while SPY has returned +5.9% and +4.6%, respectively.

OKUR support price is $3.93 and resistance is $4.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OKUR shares will trade within this expected range on the day.